Cefpiramide drug combination

A technology for cefpiramide and medicine, which is applied in the field of cefpiramide combination medicine and its preparation, and achieves the effects of stable quality, reduced adverse reactions and high medicine quality

Inactive Publication Date: 2010-09-08
邓学峰
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] In order to overcome the defects of the above-mentioned adverse reactions existing in the application of cefpiramide or its pharmaceutically acceptable salt as a drug, and improve the curative effect of the drug, the invention provides a cefpiramide combination drug and a preparation method thereof

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] The cefpiramide combination medicine provided by the present embodiment includes the active ingredients in the following parts by weight:

[0030] Cefpiramide or cefpiramide sodium (calculated as cefpiramide) 500;

[0031] Lidocaine 100;

[0032] Reduced Glutathione 20;

[0033] Aspirin Lysinate 50.

[0034] The preparation method of the above-mentioned combination medicine comprises the following steps:

[0035] (1). Get the water for injection of 50~200 times of described cefpiramide weight, under agitation, respectively put the described amount of cefpiramide or its pharmaceutically acceptable salt, lidocaine, reduced glutathione The peptide and aspirin lysine salt were completely dissolved to prepare a solution of the drug.

[0036] The antioxidant reduced glutathione protects the oxidation and peroxidation of cefpiramide in the manufacture, storage, transportation, use, and body, so that the adverse reactions are greatly reduced, and the reduced glutathione can...

Embodiment 2

[0051] The cefpiramide combination medicine provided by the present embodiment includes the active ingredients in the following parts by weight:

[0052] Cefpiramide or cefpiramide sodium (calculated as cefpiramide) 2000;

[0053] Lidocaine 200;

[0054] Reduced Glutathione 100;

[0055] Aspirin Lysinate 100.

[0056] The preparation method of the above-mentioned combination medicine comprises the following steps:

[0057](1). Get the water for injection of 50~200 times of described cefpiramide weight, under agitation, respectively put the described amount of cefpiramide or its pharmaceutically acceptable salt, lidocaine, reduced glutathione The peptide and aspirin lysine salt were completely dissolved to prepare a solution of the drug.

[0058] The antioxidant reduced glutathione protects the oxidation and peroxidation of cefpiramide in the manufacture, storage, transportation, use, and body, so that the adverse reactions are greatly reduced, and the reduced glutathione c...

Embodiment 3

[0073] The cefpiramide combination medicine provided by the present embodiment includes the active ingredients in the following parts by weight:

[0074] Cefpiramide or cefpiramide sodium (calculated as cefpiramide) 1250;

[0075] Lidocaine 165;

[0076] Reduced Glutathione 80;

[0077] Aspirin lysine 73.

[0078] The preparation method of the above-mentioned combination medicine comprises the following steps:

[0079] (1). Get the water for injection of 50~200 times of described cefpiramide weight, under agitation, respectively put the described amount of cefpiramide or its pharmaceutically acceptable salt, lidocaine, reduced glutathione The peptide and aspirin lysine salt were completely dissolved to prepare a solution of the drug.

[0080] The antioxidant reduced glutathione protects the oxidation and peroxidation of cefpiramide in the manufacture, storage, transportation, use, and body, so that the adverse reactions are greatly reduced, and the reduced glutathione can ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a cefpiramide drug combination, which consists of the following effective ingredients in part by weight: 500 to 2000 parts of cefpiramide or pharmaceutically acceptable salt thereof (by cefpiramide), 100 to 200 parts of lidocaine, 20 to 100 parts of reduced glutathione and 50 to 100 parts of aspirin-DL-lysine. The drug combination cannot cause adverse reactions, and has a high curative effect, and moreover, the preparation method is simple and environment-friendly.

Description

technical field [0001] The invention relates to a cefpiramide combination medicine and a preparation method thereof. Background technique [0002] Cefpiramide or a pharmaceutically acceptable salt thereof is an antibacterial drug currently used clinically. Cefpiramide is a semi-synthetic third-generation cephalosporin with the molecular formula C 25 h 24 N 8 o 7 S 2 . Other names are: Fomepizole cephalosporin, Taibixin, Taibixin, Xianfupiran, Cefpiramid, Cefpiran, Sepatren, Sopatren, etc. It has a broad antibacterial spectrum, strong antibacterial effect, no absorption when taken orally, and good absorption when administered intravenously and intramuscularly. [0003] However, the existing cefpiramide injections are unstable when stored below 25°C, and the following adverse reactions may occur during administration: drug allergy, influence on gastrointestinal tract, liver, kidney, blood, nervous system, etc., drug Heat reaction, intravenous infusion pain and phlebiti...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/546A61K47/42A61K47/18A61K47/14A61P31/04
Inventor 蔡海德邓学峰
Owner 邓学峰
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap